Compartir
Información de la revista
Número
Vol. 27. Núm. 2.(marzo - abril 2022)
Editorial
Training in Hepatology: From medical school to a Ph.D. and clinical specialty program
Arturo Panduro
Ann Hepatol. 2022;27:100682
Open access
Concise reviews
Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing
Fan Yang, Kaige Deng, Haoran Zheng, Zhenting Liu, Yongchang Zheng
Ann Hepatol. 2022;27:100677
Open access
Acid-base abnormalities and liver dysfunction
Periklis Katopodis, Efthymios M. Pappas, Konstantinos P. Katopodis
Ann Hepatol. 2022;27:100675
Open access
Original articles
Introduction of a standardized protocol for cardiac risk assessment in candidates for liver transplant – A retrospective cohort analysis
Killian J. McCarthy, Daniel Motta-Calderon, Alisson Estrada-Roman, Karen M. Cajiao, Michael P. Curry, Alan Bonder, Anne-Marie Anagnostopoulos, Michael Gavin
Ann Hepatol. 2022;27:100582
Open access
Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathway
Si-Si Jin, Chun-Jing Lin, Xian-Fan Lin, Ju-Zeng Zheng, Hua-Qin Guan
Ann Hepatol. 2022;27:100584
Open access
Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis
Itzayana Rodríguez-Antonio, Guillermo N. López-Sánchez, Víctor A. Reyes-Gómez, Ericka H. Contreras-Flores, Fernanda Farías-García, Mariana Espejel-Deloiza, Marco A. Durán-Padilla, Fredy Chablé-Montero, ... Natalia Nuño-Lámbarri
Ann Hepatol. 2022;27:100651
Open access
Long-term prediction of hepatocellular carcinoma using serum autotaxin levels after antiviral therapy for hepatitis C
Wataru Ando, Fumihiko Kaneko, Satoshi Shimamoto, Koji Igarashi, Katsuya Otori, Hiroaki Yokomori
Ann Hepatol. 2022;27:100660
Open access
Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors
Kentaro Horiuchi, Tomomi Kogiso, Takaomi Sagawa, Makiko Taniai, Yoshito Kotera, Hiroto Egawa, Katsutoshi Tokushige
Ann Hepatol. 2022;27:100670
Open access
Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit
Zhangbin Chen, Yifei Ma, Zhitang Guo, Dingyuan Song, Zili Chen, Min Sun
Ann Hepatol. 2022;27:100669
Open access
Nomogram for prediction of long-term survival with hepatocellular carcinoma based on NK cell counts
Lihua Yu, Xiaoli Liu, Xinhui Wang, Dongdong Zhou, Huiwen Yan, Yuqing Xie, Qing Pu, Ke Zhang, Zhiyun Yang
Ann Hepatol. 2022;27:100672
Open access
Caffeine mitigates experimental nonalcoholic steatohepatitis and the progression of thioacetamide-induced liver fibrosis by blocking the MAPK and TGF-β/Smad3 signaling pathways
Eduardo E. Vargas-Pozada, Erika Ramos-Tovar, Consuelo Acero-Hernández, Irina Cardoso-Lezama, Silvia Galindo-Gómez, Víctor Tsutsumi, Pablo Muriel
Ann Hepatol. 2022;27:100671
Open access
Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma
Shuangmei Zhu, Yong Chen, Hong Ye, Baoqiang Wang, Xiang Lan, Hanying Wang, Sijie Ding, Xiao He
Ann Hepatol. 2022;27:100678
Open access
Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis
Wu Shu, Chen Shanjian, Lin Jinpiao, Ou Qishui
Ann Hepatol. 2022;27:100676
Open access
Brief report
Economic evaluation of long-term albumin use in cirrhosis patients from the Mexican healthcare system perspective
Carlos Moctezuma-Velazquez, Graciela Castro-Narro, Pablo Simó, Elisabet Viayna, Susana Aceituno, Maria Soler, Aldo Torre
Ann Hepatol. 2022;27:100673
Open access
Letters to the editor
Liver transplant outcomes during the COVID-19 pandemic
Manuel Mendizabal, Josefina Pages, Federico Piñero, Marcos Thompson, Marcelo O Silva
Ann Hepatol. 2022;27:100656
Open access
The role of basiliximab in renal function after liver transplantation
Mikel Gastaca
Ann Hepatol. 2022;27:100661
Open access
Prevalence of non alcoholic fatty liver disease and associated factors?
Segundo Moran
Ann Hepatol. 2022;27:100659
Open access
Reply to: “correspondence about “Efficacy and safety of basiliximab”
Mohamed Hashim, Ayman Alsebaey, Amr Ragab, Hossam Eldeen Soliman, Imam Waked
Ann Hepatol. 2022;27:100679
Open access
Publique en
Annals of Hepatology
Affiliated societies
